404 related articles for article (PubMed ID: 27933342)
21. Epstein-Barr virus infections are strongly dependent on activating and inhibitory KIR-HLA pairs after T-cell replate unrelated hematopoietic stem cell transplantation, the principles, and method of pairing analysis.
Nowak J; Gwozdowicz S; Graczyk-Pol E; Mika-Witkowska R; Rogatko-Koros M; Nestorowicz K; Szlendak U; Malinowska A; Kaczmarek B; Nasilowska-Adamska B; Tormanowska M; Szczurowska N; Szypnicki J; Witkowska A; Lasota M; Malinowska E; Halaburda K
HLA; 2019 Dec; 94 Suppl 2():40-48. PubMed ID: 31758851
[TBL] [Abstract][Full Text] [Related]
22. Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation.
Gagne K; Busson M; Bignon JD; Balère-Appert ML; Loiseau P; Dormoy A; Dubois V; Perrier P; Jollet I; Bois M; Masson D; Moine A; Absi L; Blaise D; Charron D; Raffoux C;
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1366-75. PubMed ID: 19822295
[TBL] [Abstract][Full Text] [Related]
23. Activating killer immunoglobulin-like receptor incompatibilities enhance graft-versus-host disease and affect survival after allogeneic hematopoietic stem cell transplantation.
Giebel S; Nowak I; Dziaczkowska J; Czerw T; Wojnar J; Krawczyk-Kulis M; Holowiecki J; Holowiecka-Goral A; Markiewicz M; Kopera M; Karolczyk A; Kyrcz-Krzemien S; Kusnierczyk P
Eur J Haematol; 2009 Oct; 83(4):343-56. PubMed ID: 19500138
[TBL] [Abstract][Full Text] [Related]
24. Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation.
Yu J; Venstrom JM; Liu XR; Pring J; Hasan RS; O'Reilly RJ; Hsu KC
Blood; 2009 Apr; 113(16):3875-84. PubMed ID: 19179302
[TBL] [Abstract][Full Text] [Related]
25. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia.
Cooley S; Trachtenberg E; Bergemann TL; Saeteurn K; Klein J; Le CT; Marsh SG; Guethlein LA; Parham P; Miller JS; Weisdorf DJ
Blood; 2009 Jan; 113(3):726-32. PubMed ID: 18945962
[TBL] [Abstract][Full Text] [Related]
26. Role of killer immunoglobulin-like receptor-ligand interactions in human leukocyte antigen-matched sibling hematopoietic stem cell transplantation.
Kanga U; Mourya M; Seth T; George J; Sood P; Sharma R; Saxena A; Mehra NK
Transplant Proc; 2012 May; 44(4):919-21. PubMed ID: 22564585
[TBL] [Abstract][Full Text] [Related]
27. Inhibitory killer cell immunoglobulin-like receptor (iKIR) mismatches improve survival after T-cell-repleted haploidentical transplantation.
Bastos-Oreiro M; Anguita J; Martínez-Laperche C; Fernández L; Buces E; Navarro A; Pascual C; Pérez-Corral A; Balsalobre P; Muñoz C; Kwon M; Serrano D; Perez-Martinez A; Buño I; Gayoso J; Díez-Martín JL
Eur J Haematol; 2016 May; 96(5):483-91. PubMed ID: 26133015
[TBL] [Abstract][Full Text] [Related]
28. Prognosis after unmanipulated HLA-haploidentical blood and marrow transplantation is correlated to the numbers of KIR ligands in recipients.
Zhao XY; Huang XJ; Liu KY; Xu LP; Liu DH
Eur J Haematol; 2007 Apr; 78(4):338-46. PubMed ID: 17378893
[TBL] [Abstract][Full Text] [Related]
29. Donor Killer Immunoglobulin-Like Receptor Haplotype B/x Induces Severe Acute Graft-versus-Host Disease in the Presence of Human Leukocyte Antigen Mismatch in T Cell-Replete Hematopoietic Cell Transplantation.
Hosokai R; Masuko M; Shibasaki Y; Saitoh A; Furukawa T; Imai C
Biol Blood Marrow Transplant; 2017 Apr; 23(4):606-611. PubMed ID: 28042021
[TBL] [Abstract][Full Text] [Related]
30. [Genes of killer cell immunoglobulin-like receptors and their HLA ligands after allogeneic hematopoietic stem cell transplantation in myeloid leukemia patients].
Khamaganova EG; Parovichnikova EN; Kuzmina LA; Kulikov SM; Savchenko VG
Ter Arkh; 2015; 87(11):68-77. PubMed ID: 26821420
[TBL] [Abstract][Full Text] [Related]
31. Prognostic role of KIR genes and HLA-C after hematopoietic stem cell transplantation in a patient cohort with acute myeloid leukemia from a consanguineous community.
Gaafar A; Sheereen A; Almohareb F; Eldali A; Chaudhri N; Mohamed SY; Hanbali A; Shaheen M; Alfraih F; El Fakih R; Iqneibi A; Youniss R; Elhassan T; Hashmi S; Aljurf M; Alhussein K
Bone Marrow Transplant; 2018 Sep; 53(9):1170-1179. PubMed ID: 29549293
[TBL] [Abstract][Full Text] [Related]
32. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.
Hsu KC; Keever-Taylor CA; Wilton A; Pinto C; Heller G; Arkun K; O'Reilly RJ; Horowitz MM; Dupont B
Blood; 2005 Jun; 105(12):4878-84. PubMed ID: 15731175
[TBL] [Abstract][Full Text] [Related]
33. Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation.
Zhao XY; Yu XX; Xu ZL; Cao XH; Huo MR; Zhao XS; Chang YJ; Wang Y; Zhang XH; Xu LP; Liu KY; Huang XJ
Blood Adv; 2019 Dec; 3(24):4312-4325. PubMed ID: 31869417
[TBL] [Abstract][Full Text] [Related]
34. A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation.
Verheyden S; Schots R; Duquet W; Demanet C
Leukemia; 2005 Aug; 19(8):1446-51. PubMed ID: 15973456
[TBL] [Abstract][Full Text] [Related]
35. External validation of models for KIR2DS1/KIR3DL1-informed selection of hematopoietic cell donors fails.
Schetelig J; Baldauf H; Heidenreich F; Massalski C; Frank S; Sauter J; Stelljes M; Ayuk FA; Bethge WA; Bug G; Klein S; Wendler S; Lange V; de Wreede LC; Fürst D; Kobbe G; Ottinger HD; Beelen DW; Mytilineos J; Fleischhauer K; Schmidt AH; Bornhäuser M
Blood; 2020 Apr; 135(16):1386-1395. PubMed ID: 31932846
[TBL] [Abstract][Full Text] [Related]
36. Recipient-donor KIR ligand matching prevents CMV reactivation post-haploidentical T cell-replete transplantation.
Zhao XY; Luo XY; Yu XX; Zhao XS; Han TT; Chang YJ; Huo MR; Xu LP; Zhang XH; Liu KY; Li D; Jiang ZF; Huang XJ
Br J Haematol; 2017 Jun; 177(5):766-781. PubMed ID: 28466469
[TBL] [Abstract][Full Text] [Related]
37. A retrospective analysis to evaluate if KIR B haplotype donors associate with a reduced risk of relapse in patients with haematological malignancies following haploidentical transplantation at the Blood and Bone Marrow Transplant Unit at Hammersmith Hospital ICHNHST.
Byrnes CP; Hastings A; Lacej I; Palanicawandar R; Olavarria E; Anand A
HLA; 2024 Jan; 103(1):e15214. PubMed ID: 37712429
[TBL] [Abstract][Full Text] [Related]
38. [Impact of donor KIR2DS5 genotype on outcome following haploidentical hematopoietic stem cell transplantation].
Wang H; He Y; Wang HH; Wang M; Zhai WJ; Zhou Z; Zhang RL; Zhai WH; Feng SZ; Han MZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):111-5. PubMed ID: 18315912
[TBL] [Abstract][Full Text] [Related]
39. KIR2DS4 and Its Variant KIR1D Are Associated with Acute Graft-versus-Host Disease, Cytomegalovirus, and Overall Survival after Sibling-Related HLA-Matched Transplantation in Patients with Donors with KIR Gene Haplotype A.
Wu X; Yao Y; Bao X; Zhou H; Tang X; Han Y; Ma X; Liu Y; Chen J; Zhou H; Jing S; Gu B; Xu Y; Sun A; He J; Wu D
Biol Blood Marrow Transplant; 2016 Feb; 22(2):220-225. PubMed ID: 26476204
[TBL] [Abstract][Full Text] [Related]
40. Donor KIR B Genotype Improves Progression-Free Survival of Non-Hodgkin Lymphoma Patients Receiving Unrelated Donor Transplantation.
Bachanova V; Weisdorf DJ; Wang T; Marsh SGE; Trachtenberg E; Haagenson MD; Spellman SR; Ladner M; Guethlein LA; Parham P; Miller JS; Cooley SA
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1602-1607. PubMed ID: 27220262
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
